The first question addressed to Dr Sekar focused on the dual properties of nitric oxide (NO) as being both an antioxidant and a pro-oxidant. In his answer, Dr Sekar discussed the suggestive evidence that lower doses of inhaled NO (iNO) may indeed have more antioxidant properties and that this effect is also influenced by the FiO 2 administered to the patient. The second question addressed the problems associated with use of iNO in cases with persistent pulmonary hypertension of the neonate (PPHN) in level III neonatal intensive care units (NICUs) without extracorporeal membrane oxygenation (ECMO) capabilities. The inquiry focused on the difficulties in establishing criteria to determine when patients fail iNO and require transport to an ECMO center. In his answer, Dr Sekar acknowledged that it would be very difficult to establish rigid criteria based on indices of oxygenation status, and in these situations clinical judgment cannot be substituted. Dr Seri added that his group recently published a paper in the Journal of Pediatric Surgery investigating this very topic. Their findings indicate that the dose and duration of iNO administration are predictive for the need of ECMO in neonates with meconium aspiration syndrome and PPHN. However, as these factors are influenced by the protocols of administration and weaning of iNO in a given unit, each unit should develop its own unit-specific predictability model to tackle this difficult question.
The first question addressed to Dr Clyman inquired about the association between spontaneous intestinal perforations (SIPs) and indomethacin administration, especially if the infant was exposed to prenatal steroids. In his answer, Dr Clyman referred to the results of the Trial of Indomethacin Prophylaxis in Preterms (TIPP) trial, indicating that the incidence of SIP or necrotizing enterocolitis (NEC) was unaffected by the use of prophylactic indomethacin in a population with an approximately 80% exposure to prenatal steroids. He stated there is a higher incidence of NEC in the babies who are not exposed to prenatal steroids and have a patent ductus arteriosus (PDA). This finding probably relates to the beneficial effects of antenatal steroids on gastrointestinal maturation.
The second question inquired about the success rate of PDA closure in the extremely low birth weight (ELBW) infant and whether a prolonged indomethacin course would make a difference. In his answer, Dr Clyman explained that his group found a higher success rate of permanent closure with the prolonged course, but this finding also depends on the maturity of the patient. In ELBW neonates (p27 weeks gestation), if the ductus was constricting but not closed after the second indomethacin dose, the reopening rate of the ductus arteriosus was 80% with the 3-dose indomethacin course and 45% with the 6-dose course. However, for the more immature infants at 24-or 25-weeks gestation, the reopening rate was 100% with the 3-dose indomethacin course and 100% with the 6-dose course.
The next question inquired about the effect of prophylactic indomethacin on the incidence of intraventricular hemorrhage (IVH) and the potential mechanisms of the indomethacin administration-induced decrease in the incidence of IVH. Several possibilities have been entertained regarding this protective effect, including the direct hemodynamic effects of the early closure of the PDA, the possible effect of indomethacin on vascular stability, and/ or changes in our approach to treating neonatal cardiovascular instability, resulting in an improved autoregulation of cerebral blood flow. In his answer, Dr Clyman responded that indomethacin does decrease the incidence of more severe IVH. This is unlikely to be related to the closure of the PDA itself as ductal shunts can be dissociated from IVH. Rather, indomethacin appears to have a direct effect on the cerebral vasculature, as it has been demonstrated that indomethacin alters certain basement membrane components, especially laminin, in the cerebral vessels, leading to increased stability of the vessel wall. Indeed, although indomethacin and ibuprofen are both nonselective cyclooxygenase inhibitors, evidence from a number of prophylactic ibuprofen trials suggests that ibuprofen has no benefit in decreasing the incidence of severe IVH. Finally, as for the mechanism of early IVH in the immature preterm neonate, it appears that these patients tend to develop a decrease in systemic cardiac output in the first 6-18 h after delivery and then, as their myocardium recovers, blood flow to the brain increases. Thus, it appears that IVH in the immature neonate in the immediate postnatal period is primarily an ischemia-reperfusion type of injury and inhibition of prostaglandin synthesis does not affect it. Finally, Dr Clyman added that the original theoretical reason for using ibuprofen as opposed to indomethacin to decrease the incidence of IVH is that ibuprofen has a different effect on cerebral blood flow autoregulation. Whereas indomethacin at higher blood pressures limits blood flow in the pressure passive areas, ibuprofen actually promotes blood flow at higher pressures. This observation had originally been viewed as a potential benefit because of the fear that indomethacin, by limiting blood flow at higher pressures, may cause ischemia and an increased incidence of periventricular leukomalacia. In summary, the mechanisms of the indomethacin-induced decrease in the incidence of IVH include the drug-induced increase in the stability of the vessel wall and the vasoconstriction mitigating the severity of the reperfusion injury, resulting in a decreased incidence of IVH.
The next question addressed whether Dr Clyman's group regularly performs an echocardiogram before the first dose of indomethacin in infants treated with prophylactic indomethacin to rule out the presence of duct-dependent congenital cardiac lesions. Dr Clyman stated that his group at the University of California at San Francisco (UCSF) uses prophylaxis only for babies who are p27 weeks gestation. At UCSF, they do not have bedside cardiologists available all the time, so they do not perform an echocardiogram before the first dose on a regular basis. However, they always follow their patients closely for the presence of a ductdependent congenital cardiac lesion. As he recalled, they had treated two babies with indomethacin over the years who had ductdependent lesions. Both patients developed hypoxemia as the ductus was closing in response to indomethacin, and the ductus reopened as soon as they stopped the indomethacin and started prostaglandins.
The next question addressed whether it is appropriate to feed the preterm neonate while on indomethacin. Dr Clyman explained that his group does not feed infants that are being treated with indomethacin. The decision not to feed in this situation is based on the results of animal studies indicating that indomethacin alters oxygen consumption in the gut. The other problem is that feeding also distends the intestinal lumen and mesenteric blood flow is dependent not on the arterial-venous pressure difference but the arterial-luminal pressure difference. Thus, by increasing intraluminal pressure, feeding may further compromise oxygen delivery. However, there is no evidence to suggest that the practice of not feeding indomethacin-exposed preterm neonates is the right one. Finally, he added that one recent experiential study looked at indomethacin use and breast milk feedings and found no alterations in the incidence of NEC. In summary, it remains unclear what to do.
The first question to Dr Seri inquired about the maximum dose of dopamine in the critically ill preterm or term neonate. In his answer, Dr Seri stated that he would not limit dopamine or epinephrine administration to an arbitrary number because it is not the pharmacokinetics, but the pharmacodynamics, that matters when using vasopressors. In other words, because of the downregulation of the cardiovascular adrenergic receptors and the dysregulated production of vasodilators in patients with shock, one needs to titrate the given vasopressor according to the hemodynamic response. As for dopamine, the data on the regularly quoted dose range of 2-20 mcg/kg/min originate from a doseresponse study performed in adults without hemodynamic compromise and thus receptor downregulation and dysregulated production of vasodilators. Findings from studies using high doses of dopamine (between 20-400 mcg/kg/min) or combination of dopamine with moderate-to-high doses of epinephrine suggest that when blood pressure improves, urine output improves as well. Thus, in patients with primary vasodilatory shock (such as one sees with sepsis), vasoconstriction of the renal and mesenteric circulation probably does not occur at higher doses of vasopressors and with the restoration of perfusion pressure, organ (such as renal) function recovers. However, one needs to be cautious and avoid using high doses of vasopressors when myocardial function is also compromised, as may be the case in the 1-day old ELBW neonate. If the vasopressor-induced increase in systemic vascular resistance limits cardiac output, blood pressure may be in the normal range but organ blood flow may be compromised.
The next question to Dr Seri addressed the definition of vasopressor resistance and the use of hydrocortisone for patients with vasopressor resistance. Dr Seri stated that in clinical practice, neonatologists have arbitrarily established a dose-range of dopamine where they would intervene with hydrocortisone because of the presence of presumed vasopressor resistance. Some units use 10-15 mcg/kg/min of dopamine as a cutoff point, others use 20-25 mcg/kg/min. There is no data on what dose-range should be considered as true vasopressor resistance. As for the safety of hydrocortisone administration, Dr Seri explained that although a X3 week course of relatively high-dose hydrocortisone administration starting after the first postnatal week may not have demonstrable deleterious effects on central nervous system development and function by eight years of age, we do not have any data on the potential long-term neurodevelopmental effects of early hydrocortisone administration starting during the first postnatal week when most preterm neonates receive the drug for vasopressor resistance. In addition, because of the evidence for the increased incidence of SIP in preterm neonates concomitantly exposed to hydrocortisone and indomethacin, the administration of hydrocortisone in indomethacin-treated very low birth weight (VLBW) neonates should be limited to cases with intractable vasopressor-resistant hypotension.
